Elicio Therapeutics Inc Sustainability Reports
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company that develops novel immunotherapies for the treatment of cancer and other diseases. The company utilizes its proprietary Amphiphile platform to deliver immunotherapeutics directly to the lymph nodes to generate robust T cell responses.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
LEI: 254900EE2QKYD5SGI956
FIGI: BBG00444GM11
1 reports from 2024 to 2024
